Foreign-Exchange Risk from Overseas Sales and Foreign-Currency Assets
First written in FY2016. 9 of 23 entries say "Materialised", first in FY2017-Q1. Latest entry: FY2026.
Seikagaku moved to the "Worse" side of this theme in 2016, 3 years before the typical company in this theme (2019).
The whole theme swung hardest in 2025: 71 of 159 companies on the "Worse" side.
53 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「This was due mainly to the recognition of gains on sales of investment securities and the shift from a foreign-exchange loss in the previous period to a foreign-exchange gain in the current period as a result of the weaker yen.」
The foreign-exchange loss recognized in the previous period turned into a foreign-exchange gain in the current period due to the weaker yen, reversing the negative impact of foreign-exchange movements on profit and loss. - FY2026-H1MaterialisedAnnual report
「Although overseas sales of glucan-testing in vitro diagnostic products continued to perform well, revenue was ¥5,779 million, down 1.4% year on year due to the yen being stronger than in the same period of the previous year.」
The stronger yen reduced the yen equivalent of overseas sales, with its impact appearing in the results as a 1.4% year-on-year decline in first-half LAL business revenue. - FY2025WorsenedAnnual report
「Non-operating income was ¥891 million, down 31.7%, and non-operating expenses were ¥291 million, up 535.7%. This was due mainly to the shift from foreign-exchange gains to foreign-exchange losses as a result of the stronger yen.」
The stronger yen caused foreign-exchange gains to turn into losses, increasing non-operating expenses. The overseas sales ratio was also 62.0%, excluding royalties, indicating foreign-currency exposure. - FY2025-H1MaterialisedAnnual report
「Operating income rose 71.2% to ¥2,537 million on higher revenue, but the increase narrowed as the yen appreciated toward the end of the interim period and the Company recorded a foreign-exchange loss. Ordinary income therefore rose 1.2% to ¥2,354 million.」
As the yen appreciated toward the end of the interim period, the Company recognized a ¥499 million foreign-exchange loss. Foreign-exchange movements appeared in the results as a factor narrowing the increase in ordinary income. - FY2024Higher overseas sales ratio and contribution from the weaker yenAnnual report
「The proportion of overseas sales in the current consolidated fiscal year was 60.3%, excluding royalties, and most transaction currencies were foreign currencies such as the U.S. dollar. Sharp foreign-exchange movements may therefore affect business performance.」
Reports an overseas sales ratio of 60.3%, excluding royalties, and continues to describe the potential impact of foreign-currency transactions on business performance and mitigation through foreign-currency payments for R&D expenses and forward exchange contracts. - FY2024-Q3Increase in Foreign Currency Translation Adjustment Due to Yen DepreciationAnnual report
「Net assets increased by ¥4,501 million from the end of the previous consolidated fiscal year to ¥71,718 million. This was due mainly to an increase in the foreign currency translation adjustment account resulting from the weaker yen and an increase in retained earnings following the recognition of net income attributable to owners of the parent.」
The effect of the weaker yen appeared as an increase in net assets through the increase in the foreign currency translation adjustment account. The impact of foreign-exchange movements continued to appear in the results. - FY2023-Q3Weaker yen contributed to sales and foreign-exchange gainsAnnual report
「Ordinary income fell 38.9% to ¥4,218 million, with the decline narrowing due to the recognition of foreign-exchange gains resulting from the weaker yen.」
Foreign-exchange gains resulting from the weaker yen helped narrow the decline in ordinary income. The effect of the weaker yen also appeared in sales at overseas subsidiaries. - FY2023-Q2Weaker yen and foreign-exchange gains continueAnnual report
「Ordinary income fell 43.7% to ¥3,600 million, with the decline narrowing due to the recognition of foreign-exchange gains resulting from the weaker yen and other factors.」
Foreign-exchange gains resulting from the weaker yen helped narrow the decline in ordinary income. The quarterly consolidated income statement records ¥773 million in foreign-exchange gains. - FY2023-Q1Weaker yen and foreign-exchange gains contributedAnnual report
「Ordinary income fell 62.8% to ¥1,714 million, with the decline narrowing due to the recognition of foreign-exchange gains resulting from the weaker yen and other factors.」
Foreign-exchange gains resulting from the weaker yen helped narrow the decline in ordinary income. The impact of foreign-exchange movements continued to appear in the results. - FY2021MitigatedAnnual report
「The proportion of overseas sales in the current period was 49.6%, and most transactions were conducted in foreign currencies such as U.S. dollars. Sharp foreign-exchange movements may therefore affect business performance. To mitigate this risk, the Company uses foreign-currency revenue to pay R&D expenses for overseas clinical trials and other activities, and enters into forward exchange contracts.」
Reports an overseas sales ratio of 49.6% and continued risk mitigation through foreign-currency payments for R&D expenses and forward exchange contracts. The Company recognized a ¥157 million foreign-exchange gain in the current period. - FY2021-Q2MitigatedAnnual report
「Foreign-exchange loss 63」
The foreign-exchange loss in the six-month period of the second quarter was ¥63 million, down from ¥145 million in the same period of the previous year. Foreign-exchange movements continued to affect profit and loss, but the loss narrowed. - FY2021-Q1MitigatedAnnual report
「Ordinary income fell 51.2% to ¥610 million, despite positive factors such as royalty income and a decrease in foreign-exchange losses.」
The foreign-exchange loss declined from ¥122 million in the same quarter of the previous year to ¥31 million in the current quarter, reducing the negative impact of foreign-exchange movements on earnings. - FY2020-Q3MaterialisedAnnual report
「Foreign-exchange loss 112」
The Company recognized a ¥112 million foreign-exchange loss in the nine-month period of the third quarter, showing the impact of foreign-exchange movements in the results. - FY2020-Q2MaterialisedAnnual report
「Foreign-exchange loss 145」
The Company recognized a ¥145 million foreign-exchange loss in the six-month period of the second quarter, showing the impact of foreign-exchange movements in the results. Revenue from Altis for China also declined due to foreign-exchange effects. - FY2020-Q1MaterialisedAnnual report
「Foreign-exchange loss 122」
The Company recognized a ¥122 million foreign-exchange loss as a non-operating expense in the first quarter, showing the impact of foreign-exchange movements in the results. - FY2019MitigatedAnnual report
「The Company is mitigating the risk of foreign-exchange fluctuations by paying part of its R&D expenses in U.S. dollars and entering into forward exchange contracts.」
Describes specific risk mitigation measures, including denominating part of R&D expenses in U.S. dollars and entering into forward exchange contracts. - FY2018-Q3MitigatedAnnual report
「Revenue for the nine-month period of the third quarter of the current fiscal year increased 5.8% year on year to ¥23,401 million, due to higher shipment volumes of domestic and overseas pharmaceuticals and the effect of the weaker yen.」
The weaker yen contributed to higher overseas pharmaceutical sales, with foreign-exchange movements having a positive rather than negative impact on business performance. - FY2018-Q1MitigatedAnnual report
「Ordinary income rose 205.8% to ¥1,256 million and net income attributable to owners of the parent rose 221.7% to ¥923 million, due to the shift from foreign-exchange losses to gains and gains on sales of investment securities.」
Foreign-exchange losses in the same quarter of the previous year turned into foreign-exchange gains in the current quarter, reversing the negative impact of foreign-exchange movements on earnings. - FY2017MaterialisedAnnual report
「Overseas sales of endotoxin-testing reagents and related products increased in local-currency terms, but were affected by foreign exchange rates. Sales in yen declined 0.1% year on year to ¥5.437 billion.」
The impact of foreign-exchange movements on yen-denominated LAL business revenue appeared in the full-year results as a decline. - FY2017-Q3MaterialisedAnnual report
「Consolidated net sales for the third quarter cumulative period were ¥22,128 million, down 5.6% year on year. Although unit sales of U.S. Gel-One and the overseas LAL business increased, sales were affected by the stronger yen and cuts to official drug prices in Japan.」
The stronger yen materially affected revenue, while the resulting increase in the cost ratio, among other factors, contributed to the decline in operating income. - FY2017-Q2MaterialisedAnnual report
「Operating income fell 61.8% to ¥783 million, due mainly to a higher cost ratio resulting from the stronger yen and reductions in drug prices, as well as increased R&D expenses associated with the progress of the open-label study of SI-6603, a treatment for lumbar disc herniation in the United States. Despite negative factors including a decrease in gains on sales of investment securities and the recognition of foreign-exchange valuation losses, ordinary income fell 46.5% to ¥1,376 million because royalty income provided a positive contribution.」
Foreign-exchange valuation losses arose as the yen appreciated, materially affecting both operating income and ordinary income. - FY2017-Q1MaterialisedAnnual report
「Ordinary income fell 70.2% to ¥410 million, due mainly to a decrease in gains on sales of investment securities and foreign-exchange valuation losses on foreign-currency-denominated assets held as the yen appreciated.」
States that foreign-exchange valuation losses on foreign-currency-denominated assets due to the stronger yen actually affected ordinary income. - FY2016First statedAnnual report
「As the proportion of overseas sales has increased in recent years, changes in foreign-exchange rates may affect business performance.」
Although the weaker yen boosted overseas sales in the current period, foreign-exchange valuation factors related to foreign-currency-denominated assets due to the stronger yen at period-end affected ordinary income.